MX2010005187A - Derivados de 1,2,3-triazol para uso como inhibidores de estearoil-coenzima a desaturasa. - Google Patents

Derivados de 1,2,3-triazol para uso como inhibidores de estearoil-coenzima a desaturasa.

Info

Publication number
MX2010005187A
MX2010005187A MX2010005187A MX2010005187A MX2010005187A MX 2010005187 A MX2010005187 A MX 2010005187A MX 2010005187 A MX2010005187 A MX 2010005187A MX 2010005187 A MX2010005187 A MX 2010005187A MX 2010005187 A MX2010005187 A MX 2010005187A
Authority
MX
Mexico
Prior art keywords
stearoyl
triazole derivatives
coa desaturase
desaturase inhibitors
relates
Prior art date
Application number
MX2010005187A
Other languages
English (en)
Inventor
Anne Marie Jeanne Bouillot
Alain Laroze
Lionel Trottet
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MX2010005187A publication Critical patent/MX2010005187A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

La presente invención se refiere a compuestos de triazol sustituidos de la fórmula (I): (ver fórmula (I)) y sales farmacéuticamente aceptables de los mismos, a composiciones farmacéuticas que los contienen y a su uso en medicina; en particular, la invención se refiere a compuestos para modular la actividad de SCD.
MX2010005187A 2007-11-09 2008-11-07 Derivados de 1,2,3-triazol para uso como inhibidores de estearoil-coenzima a desaturasa. MX2010005187A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0722077.5A GB0722077D0 (en) 2007-11-09 2007-11-09 Compounds
PCT/EP2008/065104 WO2009060053A1 (en) 2007-11-09 2008-11-07 1, 2, 3-triazole derivatives for use as stearoyl-coa desaturase inhibitors

Publications (1)

Publication Number Publication Date
MX2010005187A true MX2010005187A (es) 2010-05-27

Family

ID=38858481

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005187A MX2010005187A (es) 2007-11-09 2008-11-07 Derivados de 1,2,3-triazol para uso como inhibidores de estearoil-coenzima a desaturasa.

Country Status (32)

Country Link
US (2) US8486977B2 (es)
EP (2) EP2207770B1 (es)
JP (1) JP5491407B2 (es)
KR (1) KR101577080B1 (es)
CN (1) CN101918376B (es)
AT (1) ATE512140T1 (es)
AU (1) AU2008324172B2 (es)
BR (1) BRPI0820471A2 (es)
CA (1) CA2705113C (es)
CO (1) CO6270331A2 (es)
CR (1) CR11482A (es)
CY (2) CY1112233T1 (es)
DK (2) DK2207770T3 (es)
DO (1) DOP2010000137A (es)
EA (1) EA016621B1 (es)
ES (2) ES2457521T3 (es)
GB (1) GB0722077D0 (es)
HK (2) HK1141528A1 (es)
HR (2) HRP20110552T1 (es)
IL (1) IL205152A (es)
MA (1) MA31801B1 (es)
ME (1) ME01962B (es)
MX (1) MX2010005187A (es)
MY (1) MY163126A (es)
NZ (1) NZ584725A (es)
PL (2) PL2368887T3 (es)
PT (2) PT2207770E (es)
RS (2) RS51918B (es)
SI (2) SI2207770T1 (es)
UA (1) UA107324C2 (es)
WO (1) WO2009060053A1 (es)
ZA (1) ZA201002596B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0722077D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
GB0722075D0 (en) 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
JP5529121B2 (ja) * 2008-09-15 2014-06-25 ダイキン工業株式会社 水性重合体分散組成物および表面処理剤
MX2011004125A (es) * 2008-10-21 2011-05-19 Metabolex Inc Agonistas del receptor gpr120 de arilo y usos de los mismos.
FR2974089B1 (fr) * 2011-04-18 2014-04-25 Univ Nice Sophia Antipolis Derives de l'acadesine, produits et compositions les comprenant, leurs utilisations therapeutiques et leurs procedes de synthese.
WO2013134546A1 (en) 2012-03-07 2013-09-12 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
KR101676208B1 (ko) * 2012-09-17 2016-11-14 에프. 호프만-라 로슈 아게 트라이아졸 카복스아미드 유도체
IL227890A0 (en) * 2013-08-08 2014-01-30 Galderm Therapeutics Ltd Antiaging compounds containing bile acid and fatty acid conjugates
AU2016211292B2 (en) * 2015-01-30 2020-05-07 Neurocrine Biosciences, Inc. Substituted triazoles and methods relating thereto
KR20180036318A (ko) * 2016-09-30 2018-04-09 경북대학교 산학협력단 2-아미노-2-(1-도데실-1h-1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체를 유효성분으로 포함하는 퇴행성 신경질환 및 우울증 예방 또는 치료용 약학적 조성물
WO2018081167A1 (en) 2016-10-24 2018-05-03 Yumanity Therapeutics Compounds and uses thereof
WO2018129403A1 (en) * 2017-01-06 2018-07-12 Yumanity Therapeutics Methods for the treatment of neurological disorders
KR102292989B1 (ko) 2017-03-29 2021-08-26 재단법인 아산사회복지재단 S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
JP2021522253A (ja) * 2018-04-25 2021-08-30 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
KR102017324B1 (ko) * 2018-04-30 2019-09-02 경북대학교 산학협력단 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도
CA3127791A1 (en) 2019-01-24 2020-07-30 Yumanity Therapeutics, Inc. Compounds and uses thereof
CN114656414B (zh) * 2022-05-24 2022-08-23 常熟华虞环境科技有限公司 三氮唑改性二氧化钛光催化剂及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US5223261A (en) 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US20070087363A1 (en) 1998-12-22 2007-04-19 Myriad Genetics, Incorporated Therapeutic methods, compounds and compositions
AU2001247228B2 (en) 2000-02-24 2007-01-18 Wisconsin Alumni Research Foundation Stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
US7232662B2 (en) 2000-09-26 2007-06-19 Xenon Pharmaceuticals Inc. Methods and compositions employing a novel stearoyl-CoA desaturase-hSCD5
MY141559A (en) * 2002-04-26 2010-05-14 Lilly Co Eli Triazole derivatives as tachykinin receptor antagonists
WO2005000821A1 (en) * 2003-06-12 2005-01-06 Eli Lilly And Company Tachykinin receptor antagonists
BRPI0412348A (pt) 2003-07-30 2006-09-05 Xenon Pharmaceuticals Inc derivados de piperazina e seu uso como agentes terapêuticos
JP4831577B2 (ja) 2003-07-30 2011-12-07 ゼノン・ファーマシューティカルズ・インコーポレイテッド ピリダジン誘導体および治療剤としての用途
WO2007046867A2 (en) 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
WO2007046868A2 (en) 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Thiazolidine derivatives and their uses as therapeutic agents
WO2008073461A2 (en) * 2006-12-11 2008-06-19 Wyeth Ion channel modulators
GB0625654D0 (en) * 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
GB0625604D0 (en) * 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
GB0625605D0 (en) * 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
WO2008104524A1 (en) * 2007-02-28 2008-09-04 Smithkline Beecham Corporation Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
EP2148868A1 (en) * 2007-05-15 2010-02-03 NeuroSearch A/S Novel aromatic heterocyclic carboxylic acid amide derivatives useful as potassium channel modulators
GB0714129D0 (en) 2007-07-19 2007-08-29 Smithkline Beecham Corp compounds
GB0715055D0 (en) 2007-08-02 2007-09-12 Smithkline Beecham Corp Compounds
GB0721419D0 (en) 2007-10-31 2007-12-12 Smithkline Beecham Corp Compounds
GB0722075D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
GB0722077D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
GB0810913D0 (en) 2008-06-13 2008-07-23 Smithkline Beecham Corp Comppounds

Also Published As

Publication number Publication date
ES2457521T3 (es) 2014-04-28
CA2705113C (en) 2016-01-05
EP2207770B1 (en) 2011-06-08
CA2705113A1 (en) 2009-05-14
ME01962B (en) 2012-02-29
IL205152A0 (en) 2010-11-30
EP2368887A1 (en) 2011-09-28
EP2368887B1 (en) 2014-02-26
PL2207770T3 (pl) 2011-10-31
US20100297054A1 (en) 2010-11-25
BRPI0820471A2 (pt) 2015-06-16
US8486977B2 (en) 2013-07-16
PT2368887E (pt) 2014-05-15
SI2207770T1 (sl) 2011-09-30
JP2011503031A (ja) 2011-01-27
AU2008324172A1 (en) 2009-05-14
DK2368887T3 (da) 2014-04-14
CR11482A (es) 2010-07-09
MA31801B1 (fr) 2010-10-01
UA107324C2 (uk) 2014-12-25
CN101918376A (zh) 2010-12-15
IL205152A (en) 2013-10-31
EP2368887B8 (en) 2014-04-16
PT2207770E (pt) 2011-09-01
HRP20110552T1 (hr) 2011-09-30
HRP20140346T1 (hr) 2014-05-09
WO2009060053A1 (en) 2009-05-14
NZ584725A (en) 2012-05-25
GB0722077D0 (en) 2007-12-19
RS51918B (en) 2012-02-29
KR20100095574A (ko) 2010-08-31
MY163126A (en) 2017-08-15
PL2368887T3 (pl) 2014-07-31
EP2207770A1 (en) 2010-07-21
EA016621B1 (ru) 2012-06-29
HK1160467A1 (en) 2012-08-17
HK1141528A1 (en) 2010-11-12
US20130281499A1 (en) 2013-10-24
DOP2010000137A (es) 2010-08-15
CN101918376B (zh) 2013-11-06
AU2008324172B2 (en) 2012-03-15
SI2368887T1 (sl) 2014-05-30
ZA201002596B (en) 2010-12-29
CO6270331A2 (es) 2011-04-20
US9051281B2 (en) 2015-06-09
KR101577080B1 (ko) 2015-12-11
EA201070588A1 (ru) 2010-10-29
RS53294B (en) 2014-08-29
DK2207770T3 (da) 2011-09-12
JP5491407B2 (ja) 2014-05-14
CY1112233T1 (el) 2015-12-09
CY1115058T1 (el) 2016-12-14
ATE512140T1 (de) 2011-06-15
ES2366422T3 (es) 2011-10-20

Similar Documents

Publication Publication Date Title
MX2010005187A (es) Derivados de 1,2,3-triazol para uso como inhibidores de estearoil-coenzima a desaturasa.
WO2008074824A3 (en) Isoquinolinecarboxamides as inhibitors of stearoyl-coa desaturase (scd)
WO2008074834A3 (en) Isoquinolinecarboxamides as inhibitors of stearoyl-coa desaturase (scd)
WO2008074832A3 (en) Isoquinolinecarboxamides as inhibitors of stearoyl-coa desaturase ( scd)
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
MX2010014234A (es) Compuestos pirazol 436.
MX2009005357A (es) Derivados de hidantoina usados como inhibidores de metaloproteinasas de matriz.
EA201071094A1 (ru) Тризамещенные 1,2,4-триазолы в качестве модуляторов никотиновых ацетилхолиновых рецепторов
MX2009013501A (es) Compuestos piperidinicos y sus usos.
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
MX2010013310A (es) Derivados de heterociclil urea para el tratamiento de infecciones bacterianas.
WO2008074833A3 (en) Compounds
MY148732A (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
IL191670A0 (en) Compounds for the inhibition of apoptosis
MX2023011057A (es) Derivados de indolina como inhibidores de receptores de dominio de discoidina 1 (ddr1) y receptores de dominio de discoidina 2 (ddr2).
UA87327C2 (ru) Производные бензимидазола, композиция, которая их содержит, их получение и применение
UA99734C2 (ru) Производные азабифениламинобензойной кислоты как ингибиторы dhodh
WO2010142956A3 (en) Aroylthiourea and arylthiocarbonylurea derivatives

Legal Events

Date Code Title Description
FG Grant or registration